| 词条 | Gp100:209-217(210M) |
| 释义 |
Gp100:209-217(210M) is a synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210.[1] It is often referred to as the gp100 cancer vaccine which can also include other peptides based on gp100 (for example 280-288(288V) [2][3]). Clinical trialsIt gave good results in a trial for advanced melanoma when used in combination with interleukin-2.[4] Another trial against Ipilimumab in advanced melanoma suggested Ipilimumab may be better than the gp100 vaccine alone.[5] References1. ^http://www.cancer.gov/drugdictionary/?CdrID=476335 {{antineoplastic-drug-stub}}{{vaccine-stub}}2. ^http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=492712 3. ^{{cite web |url=http://abstract.asco.org/AbstView_74_47740.html |title=Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma |year=2010}} 4. ^{{cite news |url=https://www.reuters.com/article/idUSN2934064820090530 |title=Vaccine shows promise in advanced melanoma -study |date=30 May 2009 | work=Reuters}} 5. ^http://www.genengnews.com/gen-news-highlights/bms-ipilimumab-proves-itself-in-metastatic-melanoma-patients/81243496/ 2 : Cancer vaccines|Experimental cancer treatments |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。